Swiss pharmaceutical firm Roche has sounded alarm against clinical trials conducted by Zydus Lifesciences on its biologic drug Perjeta, a widely-used breast cancer treatment. The Swiss company has filed a complaint against the Indian drug maker over alleged critical gaps in the clinical trial of a drug originally developed by Roche
/PRNewswire/ The "Global Breast Cancer Immunotherapy Market & Clinical Trials Forecast 2028" report has been added to ResearchAndMarkets.com s offering..
New cancer treatments offered at home from one of Europe’s largest cancer centres Date published: 26 April 2021
Jean Woods, the first Phasgo patient having treatment at home
One of Europe’s largest cancer centres, The Christie NHS Foundation Trust, has become the first in the country to provide a treatment called Phesgo for breast cancer patients in their own homes.
Phesgo is a combination of Herceptin (Trastuzumab) and Perjeta (Pertuzumab).
Trastuzumab and Pertuzumab are two very effective cancer drugs used to treat one of the more aggressive types of breast cancer (the HER2-positive genetic variant) once it has spread throughout the body.